Medicinal cannabis for schizophrenia - NeuRA Library

Medicinal cannabis

What is medicinal cannabis for schizophrenia?

Countries are increasingly allowing cannabinoids (tetrahydrocannabinol [THC] and cannabidiol [CBD]) to be made available for medicinal purposes, including for the treatment of mental disorders. Medicinal cannabis refers to any part of the cannabis plant, such as flowers, buds, leaves, or full plant extracts. Pharmaceutical cannabinoids refer to pharmaceutical-grade medicinal extracts with defined and standardised THC, CBD, or a combination of both, and synthetic cannabinoid derivatives.

What is the evidence for cannabinoids for schizophrenia?

Moderate to low quality evidence finds no improvement in overall and positive symptoms with adjunctive CBD or THC compared to placebo. Negative and cognitive symptoms may worsen with adjunctive THC.

September 2020

Image: ©Lifeking – stock.adobe.com

Last updated at: 4:30 am, 15th October 2021

To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

Tags: Medicinal cannabis

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.

RELATED TOPICS

Cannabis

This podcast contains information about cannabis. Here we explain what cannabis is, its legal status, its effects on the brain and body, and its use as a treatment. November 2020

Endocannabinoids

What are endocannabinoids? The endocannabinoid system is an endogenous biological system that regulates functions including cognition, sleep, energy metabolism, and inflammation. It modulates different neurotransmitter systems in the brain, including dopamine, glutamate, and GABA using two major lipid-based mediators, anandamide and arachidonoyl-sn-glycerol, that act through type one and type two cannabinoid receptors. Exogenous cannabinoids, such as delta-9-tetrahydrocannabinol (THC), the main psychoactive components of cannabis, and cannabidiol (CBD), impact on the endocannabinoid system. While disturbance of the endocannabinoid system after cannabis consumption has been associated with increased risk of psychotic illness, CBD alone has shown anti-inflammatory and antipsychotic properties. What is…

Substance use

How is substance use related to schizophrenia? Various lines of evidence suggest an association between substance use and psychosis. Experimental studies and surveys of users provide evidence that cannabis and amphetamine use can produce transient, and usually mild, psychotic experiences or recurrence of psychotic symptoms in individuals with a history of psychosis. Further, neuroimaging studies have found clear similarities between functional networks impaired by cannabis use and those known to be implicated in the pathogenesis of schizophrenia. What is the evidence for substance use as a risk factor for schizophrenia? Tobacco Moderate quality evidence finds a small to medium-sized increased…

Drug and alcohol use

What is comorbid drug and alcohol use? Drug and alcohol misuse, abuse or dependence are concerns for people with schizophrenia due to the association with poor clinical and social outcomes, including high rates of suicide, HIV, homelessness, aggression and incarceration. Moreover, substance use places additional burden on patients, families, psychiatric services, and government resources due to high rates of treatment non-adherence and relapse. This topic covers outcomes for people with schizophrenia and comorbid substance use (termed ‘dual diagnosis’). Please also see the topic on rates of comorbid substance use, as well as substance use as a risk factor for schizophrenia. What…

Drug and alcohol use

How is drug and alcohol use related to schizophrenia? Drug and alcohol use, abuse or dependence are concerns due to the association with high rates of suicide, HIV, homelessness, aggression and incarceration. Moreover, comorbid substance use places additional burden on patients, families, psychiatric services, and government resources due to high rates of treatment non-adherence and relapse. This topic presents the rates of drug and alcohol use in people with schizophrenia spectrum disorders. Please also see the topic on the effects of drug and alcohol use on the course and outcomes of these disorders. What is the evidence for comorbid drug…